CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Salix Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00329

Overview

Case Number 1:17-cv-00329
Filing Date 2017-03-27
Status Terminated
Termination Date 2019-08-02
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

7 Attorneys Listed

Andrew Russell

Shaw Keller LLP

Tel: +1 (302) 298-0704

1105 North Market St., 12th Floor, I. M. Pei Building

Samantha M. Lerner

Email: slerner@winston.com

Ryan B. Hauer

UNDELIVERABLE EMAIL 5/26/20

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Jason Z. Pesick

Email: jpesick@winston.com

George C. Lombardi

Email: glombardi@winston.com

Eimeric Reig-Plessis

Email: ereigplessis@winston.com

Plaintiff

Dr. Falk Pharma GmbH Operating Company

Represented By

5 Attorneys Listed

Kristen Healey Cramer

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320
Fax: +1 (302) 777-4224

1313 North Market Street, Suite 1200

Kenneth Mueller

Email: kenneth.mueller@wbd-us.com

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Salix Pharmaceuticals, Inc. Operating Company

Represented By

5 Attorneys Listed

Kristen Healey Cramer

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320
Fax: +1 (302) 777-4224

1313 North Market Street, Suite 1200

Kenneth Mueller

Email: kenneth.mueller@wbd-us.com

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 3 proceedings
🏛️
USPTO PTAB Trials 3 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 3 U.S. Courts: 3
USPTO PTAB Trial 2016-07-11
IPR2016-01409

MycoNovo, Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2016-07-08
IPR2016-01386

Mylan Pharmaceuticals Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2015-12-08
IPR2016-00297

GeneriCo, LLC et al. v. SALIX PHARMACEUTICALS, LTD. et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2015-06-26
1:15-cv-00109

Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc.

Asserted Patent
Status: WVND
U.S. District Court 2015-01-08
1:15-cv-00027

Salix Pharmaceuticals Inc. v. Novel Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-02-18
1:14-cv-00213

Salix Pharmaceuticals Inc. v. G & W Laboratories, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8865688
Compositions and methods for treatment of bowel diseases with granulated mesalamine
Filed: 2009-10-02
Issued: 2014-10-21
Active (3.4 yrs remaining) +211d PTA
Expires: 2030-05-01

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+211 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

18

Dispositive

0

Granted

0

Denied

0

Pending / Review

12

Motions by Category

Claim Construction / Markman Filing 9 Procedural / Extension Motion 9

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION and [Proposed] Order to Extend Time for Expert Reports by Teva Pharmaceuticals USA, Inc.. (Russell, Andrew) (Entered: 07/11/2019)
Entry #59 • 2019-07-11 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 59 STIPULATION and Order to Extend Time for Expert Reports, ORDER, Setting Scheduling Order Deadlines: Expert Discovery due by 9/6/2019. Signed b...
Entry #— • 2019-07-11
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME (and proposed order) service of opening expert reports, service of responsive expert reports and close of expert discovery to July 15...
Entry #58 • 2019-06-28 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 58 STIPULATION TO EXTEND TIME (and proposed order) service of opening expert reports, service of responsive expert reports and close of expert di...
Entry #— • 2019-06-28
Procedural / Extension Motion Pending / Under Review
STIPULATION and [Proposed] Order to Extend Time of the Service of Expert Reports by Teva Pharmaceuticals USA, Inc.. (Russell, Andrew) (Entered: 06/14/2019)
Entry #57 • 2019-06-14 Document →
Claim Construction / Markman Filing Pending / Under Review
[SEALED] Letter to The Honorable Colm F. Connolly from Karen E. Keller - re Markman Hearing. (Keller, Karen) (Entered: 05/15/2019)
Entry #51 • 2019-05-15 Document →

Docket Entries

(102 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2110500.) - filed by Salix Pharmaceuticals, Inc., Dr. Falk Pharma GmbH. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jcs) (Entered: 03/27/2017)

Entry #1 • 2017-03-27
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2110500.) - filed by Salix Pharmaceuticals, Inc., Dr. Falk Pharma GmbH. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jcs) (Entered: 03/27/2017)

Entry #1 • 2017-03-27
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2110500.) - filed by Salix Pharmaceuticals, Inc., Dr. Falk Pharma GmbH. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jcs) (Entered: 03/27/2017)

Entry #1 • 2017-03-27
2

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: February 14, 2017. Date of Expiration of Patent: May 1, 2030.Thirty Month Stay Deadline: 8/14/2019. (jcs) (Entered: 03/27/2017)

Entry #2 • 2017-03-27
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 03/27/2017)

Entry #3 • 2017-03-27
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc